ZEV ARYEH WAINBERG, MD
Radiology in Los Angeles, CA
License number
California A82044
Category
Osteopathic Medicine
Type
Hematology & Oncology
License number
California A82044
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California A82044
Category
Radiology
Type
Surgery
Address
Address
100 Medical Plz #510, Los Angeles, CA 90095
Phone
(310) 829-5471
(310) 829-6192 (Fax)
(310) 829-6192 (Fax)
Personal information
See more information about ZEV ARYEH WAINBERG at radaris.comName
Address
Phone
1440 Rexford Dr, Los Angeles, CA 90035
1917 Hillsboro Ave, Los Angeles, CA 90035
Professional information
Dr. Zev A Wainberg, Santa Monica CA - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
UCLA Santa Monica Hmtlgy/Onclgy
2020 Santa Monica Blvd SUITE 600, Santa Monica 90404
(310) 829-5471 (Phone)
2020 Santa Monica Blvd SUITE 600, Santa Monica 90404
(310) 829-5471 (Phone)
Certifications:
Hematology, 2006, Internal Medicine, 2003, Medical Oncology, 2006
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
UCLA Santa Monica Hmtlgy/Onclgy
2020 Santa Monica Blvd SUITE 600, Santa Monica 90404
Healtheast Saint John's Hospital
1575 Beam Ave, Maplewood 55109
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
UCLA Medical Center, Santa Monica
1250 16Th St, Santa Monica 90404
2020 Santa Monica Blvd SUITE 600, Santa Monica 90404
Healtheast Saint John's Hospital
1575 Beam Ave, Maplewood 55109
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
UCLA Medical Center, Santa Monica
1250 16Th St, Santa Monica 90404
Education:
Medical School
Tel Aviv University / Sackler Faculty of Medicine
Montefiore Medical Center-Moses Division
UCLA Med Ctr
Tel Aviv University / Sackler Faculty of Medicine
Montefiore Medical Center-Moses Division
UCLA Med Ctr
Zev Aryeh Wainberg, Santa Monica CA
Specialties:
Internal Medicine, Hematology, Medical Oncology, Hematology & Oncology
Work:
Ucla Dept Medicine Professional Group
2336 Santa Monica Blvd, Santa Monica, CA 90404 Ucla Medical Group-W LA
200 Ucla Medical Plz, Los Angeles, CA 90095
2336 Santa Monica Blvd, Santa Monica, CA 90404 Ucla Medical Group-W LA
200 Ucla Medical Plz, Los Angeles, CA 90095
Education:
Sackler School Of Medicine (2000)
Novel Antibodies Against Cancer Target Block Tumor Growth, Angiogenesis And Metastatis
US Patent:
2011014, Jun 16, 2011
Filed:
Apr 3, 2009
Appl. No.:
12/936189
Inventors:
Robert E. Reiter - Los Angeles CA, US
Zev Wainberg - Los Angeles CA, US
Zev Wainberg - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/395, C12N 5/16, C07K 16/18, C12Q 1/02, G01N 33/574
US Classification:
4241351, 435326, 5303875, 5303873, 4241371, 435 29, 435 723
Abstract:
The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
Identification Of Predictive Markers Of Response To Dasatinib In Human Colon Cancer
US Patent:
2011016, Jul 7, 2011
Filed:
Jan 23, 2009
Appl. No.:
12/863207
Inventors:
Dennis J. Slamon - Woodland Hills CA, US
Richard S. Finn - Encino CA, US
Judy Dering - Westlake Village CA, US
J. Randolph Hecht - Los Angeles CA, US
Zev A. Wainberg - Los Angeles CA, US
Edwin A. Clark - Pennington NJ, US
Charles L. Ginther - Los Angeles CA, US
Richard S. Finn - Encino CA, US
Judy Dering - Westlake Village CA, US
J. Randolph Hecht - Los Angeles CA, US
Zev A. Wainberg - Los Angeles CA, US
Edwin A. Clark - Pennington NJ, US
Charles L. Ginther - Los Angeles CA, US
Assignee:
BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ
International Classification:
A61K 31/506, C12Q 1/02, C12Q 1/68, A61P 35/00
US Classification:
51425219, 435 29, 435 611, 435 61
Abstract:
Methods and compositions are provided useful in the diagnosis, treatment and management of cancers wherein cancer cells express certain polynucleotides and/or polypeptides that are differentially expressed in colon cancer subtypes that are sensitive to therapy with abl kinase inhibitors and src kinase inhibitors. In particular, PTK-7, PLK-2 and PLK-3 could be identified as markers for determining the responsiveness of cancer to dasatinib.
Novel Antibodies Against Cancer Target Block Tumor Growth, Angiogenesis And Metastasis
US Patent:
2011008, Apr 14, 2011
Filed:
Sep 30, 2010
Appl. No.:
12/895661
Inventors:
Robert E. Reiter - Los Angeles CA, US
Zev Wainberg - Los Angeles CA, US
Zev Wainberg - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/395, C12N 5/12, C07K 16/18, G01N 33/53, A61P 35/00
US Classification:
4241351, 435346, 5303871, 5303891, 5303873, 4241301, 4241411, 435 71
Abstract:
The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.